Increased SEC document review by CDRH reflects boom in device M&A, stock offering activity.
This article was originally published in The Gray Sheet
Executive SummaryDEVICE SEC DOCUMENT REVIEW BY FDA ON THE RISE, reflecting the vigorous growth in mergers and acquisitions and public stock offerings in the device industry. FDA is receiving Securities and Exchange Commission filings on a daily basis, a marked increase compared to the weekly SEC document review requests it typically has received in the past.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.